Association between nutritional status and migraine in the pediatric population: A systematic review and meta-analysis (P14-9.011)

Objective:

To evaluate the association between migraine and nutritional status in the pediatric population

Background:

An association between nutritional status and migraine has been previously reported; however, this relationship has only been studied in adults, but not in the pediatric population.

Design/Methods:

We searched in PubMed/Medline, Scopus, Web of Science, Ovid Medline, and Embase until August 2021. We included observational studies that evaluated the association between migraine and nutritional status (underweight, overweight, obese, and excess weight) in the pediatric population (children and adolescents). Normal weight was the comparator. The outcome was migraine (all types, episodic and chronic). We performed meta-analyses using a random-effects model to estimate the pooled effects for each outcome. Sensitivity analysis was performed according to study design and risk of bias (using the Newcastle-Ottawa Scale). We assessed the certainty of evidence using the GRADE approach.

Results:

Eight out of 1369 studies were selected (6 cross-sectional, 1 case-control and 1 cohort), covering 16,556 patients. The overall certainty of the evidence was very low for the association between overweight, obesity, and excess weight with migraine. However, in sensitivity analysis, meta-analyses of studies with low risk of bias found that the overweight population probably increase the odds of migraine (OR: 1.70; 95% CI: 1.14 to 2.53; I2 = 32.3%, p=0.224) and that excess weight may increase the odds of migraine (OR: 1.58; 95% CI: 1.06 to 2.35; I2 = 83.7%, p=0.002). Also, the cohort and case-control designs found that obesity probably increases the odds of migraine. We found no studies analyzing the association between underweight and migraine.

Conclusions:

We found that the associations between nutritional status and migraine were uncertain. Studies with better methodology quality reported increased risk. More studies of this type are therefore needed to better characterize the association. Disclosure: Mr. Vicuña has nothing to disclose. Mr. Soriano-Moreno has nothing to disclose. Mr. De Los Rios Pinto has nothing to disclose. Miss Díaz Ledesma has nothing to disclose. Mr. Fernandez-Guzman has nothing to disclose. Carlos Alva-Diaz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche Farma. Carlos Alva-Diaz has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche Farma. The institution of Carlos Alva-Diaz has received research support from Roche farma.